{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:09Z","timestamp":1786118949463,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Chronic active Epstein\u2013Barr virus (EBV) infection (CAEBV) is a rare but life-threatening EBV-positive lymphoproliferative disorder. Currently, treatment options for CAEBV are limited. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way to cure CAEBV. Here, we report a rare case of CAEBV manifesting as massive pericardial effusion that was successfully treated with programmed cell death protein-1 (PD-1) blockade immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 36-year-old woman with intermittent chest distress and dyspnea for 8 months was admitted to our center on October 25, 2021. Laboratory tests showed leukocytopenia and elevated liver enzyme levels. Initial echocardiography revealed massive pericardial effusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>High levels of EBV-DNA were detected in the pericardial fluid by metagenomic next-generation sequencing. The pathological diagnosis of her left inguinal lymph node and skin lesions revealed systemic CAEBV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received sintilimab injection at a dose of 200\u2009mg every 2 weeks in combined with lenalidomide 10\u2009mg once daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient achieved complete resolution of pericardial effusion 5 months after PD-1 blockade immunotherapy without apparent adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>CAEBV is a rare but life-threatening EBV-positive lymphoproliferative disease. We present a rare case of massive pericardial effusion caused by systemic CAEBV, which was successfully treated with sintilimab. This case highlights the promising curative effect of PD-1 blockade immunotherapy in systemic CAEBV, especially for patients not suitable for allo-HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000030298","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T10:00:43Z","timestamp":1661853643000},"page":"e30298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Massive pericardial effusion due to chronic active Epstein\u2013Barr virus infection successfully treated with PD-1 blockade: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-5517","authenticated-orcid":false,"given":"Yubo","family":"Pi","sequence":"first","affiliation":[{"name":"Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-associated T\/NK\u2013cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases.","volume":"119","author":"Kimura","year":"2012","journal-title":"Blood"},{"key":"R2-20250707","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdp064","article-title":"Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.","volume":"20","author":"Cohen","year":"2009","journal-title":"Ann Oncol"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fped.2019.00014","article-title":"Advances in the study of chronic active epstein-barr virus infection: clinical features under the 2016 who classification and mechanisms of development.","volume":"7","author":"Arai","year":"2019","journal-title":"Front Pediatr"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00246-008-9343-8","article-title":"Cardiovascular complications associated with chronic active Epstein-Barr virus infection.","volume":"30","author":"Muneuchi","year":"2009","journal-title":"Pediatr Cardiol"},{"key":"R5-20250707","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/bloodadvances.2021005291","article-title":"High risk of relapsed disease in patients with NK\/T-cell chronic active Epstein-Barr virus disease outside of Asia.","volume":"6","author":"Davila Saldana","year":"2022","journal-title":"Blood Adv"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/bloodadvances.2020001451","article-title":"Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.","volume":"4","author":"Yonese","year":"2020","journal-title":"Blood Adv"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?.","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front Immunol"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.2019003886","article-title":"Nivolumab treatment of relapsed\/refractory Epstein-Barr virus\u2013associated hemophagocytic lymphohistiocytosis in adults.","volume":"135","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"R9-20250707","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-017-2192-6","article-title":"How we treat chronic active Epstein-Barr virus infection.","volume":"105","author":"Sawada","year":"2017","journal-title":"Int J Hematol"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2018-03-785931","article-title":"How I treat T-cell chronic active Epstein-Barr virus disease.","volume":"131","author":"Bollard","year":"2018","journal-title":"Blood"},{"key":"R11-20250707","doi-asserted-by":"crossref","first-page":"710400","DOI":"10.3389\/fphar.2021.710400","article-title":"Ruxolitinib in patients with chronic active Epstein-Barr virus infection: a retrospective, single-center study.","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"R12-20250707","first-page":"811","article-title":"[Clinical features of adult patients with chronic active Epstein-Barr virus infection].","volume":"57","author":"Xu","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R13-20250707","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12519-021-00470-9","article-title":"Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.","volume":"17","author":"Luo","year":"2021","journal-title":"World J Pediatr"},{"key":"R14-20250707","first-page":"624","article-title":"[Chronic active Epstein-Barr virus infection with marked pericardial effusion successfully treated with allogeneic peripheral blood stem cell transplantation].","volume":"57","author":"Matsui","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"R15-20250707","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in multiple myeloma.","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:11:49Z","timestamp":1786036309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":15,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030298","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}